Published in Expert Rev Clin Pharmacol on December 02, 2013
The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease. Nat Rev Nephrol (2015) 0.79
Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med (2013) 6.17
International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2002) 2.51
Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. J Clin Oncol (2012) 2.48
Randomized controlled trial of collaborative care management of depression among low-income patients with cancer. J Clin Oncol (2008) 2.47
Bladder cancer. J Natl Compr Canc Netw (2013) 2.46
Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A (2003) 2.31
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol (2014) 2.19
A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol (2003) 1.96
Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol (2006) 1.92
Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res (2003) 1.81
Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. PLoS One (2012) 1.80
Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. Lancet Oncol (2012) 1.76
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol (2011) 1.75
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol (2012) 1.66
Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology (2010) 1.65
S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. Cancer Cell (2012) 1.64
Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer. J Urol (2012) 1.56
EphB4 expression and biological significance in prostate cancer. Cancer Res (2005) 1.53
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol (2012) 1.37
Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res (2010) 1.37
Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer. J Clin Oncol (2002) 1.28
A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs (2009) 1.26
The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer (2007) 1.23
Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol (2009) 1.21
Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin Nucl Med (2012) 1.19
Cytokine therapy: a standard of care for metastatic renal cell carcinoma? Clin Genitourin Cancer (2005) 1.15
TLR9 signaling in the tumor microenvironment initiates cancer recurrence after radiotherapy. Cancer Res (2013) 1.14
Is year of radical prostatectomy a predictor of outcome in prostate cancer? J Urol (2004) 1.11
One-year follow-up of collaborative depression care for low-income, predominantly Hispanic patients with cancer. Psychiatr Serv (2011) 1.11
Association of overall survival with glycolytic activity of castrate-resistant prostate cancer metastases. Radiology (2015) 1.10
Factors influencing post-recurrence survival in bladder cancer following radical cystectomy. BJU Int (2011) 1.08
Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer. Oncogene (2003) 1.06
Microscopic and gross extravesical extension in pathological staging of bladder cancer. J Urol (2004) 1.03
Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. J Natl Cancer Inst (2006) 1.03
Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer. J Nucl Med (2013) 1.02
SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clin Cancer Res (2003) 1.02
Differentiating mTOR inhibitors in renal cell carcinoma. Cancer Treat Rev (2013) 0.98
Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial. J Thorac Oncol (2006) 0.97
Penile cancer: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2013) 0.97
Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial. Target Oncol (2014) 0.96
Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder. J Urol (2008) 0.96
Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review. BMC Cancer (2014) 0.95
Sequencing systemic therapies for metastatic kidney cancer. Curr Treat Options Oncol (2015) 0.95
Targeted therapy in renal cancer. Ther Adv Med Oncol (2009) 0.92
Improving treatment of depression among low-income patients with cancer: the design of the ADAPt-C study. Gen Hosp Psychiatry (2007) 0.92
Cabazitaxel in prostate cancer: stretching a string. Lancet (2010) 0.92
Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors. Am J Clin Oncol (2011) 0.91
Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm. Mol Cancer Ther (2012) 0.91
Natural history of surgically treated bladder carcinoma with extravesical tumor extension. Cancer (2003) 0.91
Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Invest New Drugs (2014) 0.90
A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. Cancer (2014) 0.90
A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res (2006) 0.90
Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients. Cancer (2004) 0.90
Angiogenesis-targeted therapies in prostate cancer. Clin Prostate Cancer (2004) 0.89
Postchemotherapy residual masses in advanced seminoma: current management and outcomes. Expert Rev Anticancer Ther (2005) 0.88
Discovery and preclinical evaluation of a novel class of small-molecule compounds in hormone-dependent and -independent cancer cell lines. Mol Cancer Ther (2005) 0.87
A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma. Cancer Chemother Pharmacol (2007) 0.87
The current and future application of adjuvant systemic chemotherapy in patients with bladder cancer following cystectomy. Urol Clin North Am (2005) 0.86
Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial. Clin Genitourin Cancer (2009) 0.86
A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors. Invest New Drugs (2013) 0.86
Myeloid clusters are associated with a pro-metastatic environment and poor prognosis in smoking-related early stage non-small cell lung cancer. PLoS One (2013) 0.86
Targeting angiopoietin-2 signaling in cancer therapy. Expert Opin Investig Drugs (2013) 0.86
Impact of age on treatment trends and clinical outcome in patients with metastatic renal cell carcinoma. J Geriatr Oncol (2013) 0.83
Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421. J Natl Cancer Inst (2014) 0.83
Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices. Curr Med Res Opin (2014) 0.83
Targeted α-particle therapy of bone metastases in prostate cancer. Clin Nucl Med (2013) 0.82
Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy. J Clin Oncol (2006) 0.82
Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer. Maturitas (2011) 0.82
Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer (2014) 0.82
Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium. J Cancer Res Clin Oncol (2007) 0.82
Preoperative therapy for localized prostate cancer: a comprehensive overview. Maturitas (2012) 0.81
A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer. BJU Int (2008) 0.81
Abiraterone and its place in the treatment of metastatic CRPC. Nat Rev Clin Oncol (2012) 0.81
Activin receptor inhibitors--dalantercept. Curr Oncol Rep (2015) 0.81
Oncologists' recommendations for adjuvant therapy in hormone receptor-positive breast cancer patients of varying age and health status. Clin Breast Cancer (2010) 0.80
Ipilimumab in the treatment of prostate cancer. Future Oncol (2015) 0.80
Tivozanib in the treatment of renal cell carcinoma. Biologics (2013) 0.80
New therapies for castrate-resistant prostate cancer. Expert Opin Pharmacother (2011) 0.80
Lessons learned from the bevacizumab experience. Cancer Control (2012) 0.79
Immune response to sipuleucel-T in prostate cancer. Cancers (Basel) (2012) 0.79
Comprehensive overview of axitinib development in solid malignancies: focus on metastatic renal cell carcinoma. Clin Adv Hematol Oncol (2012) 0.79
Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies. Cancer (2006) 0.79
A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell carcinoma. Int J Clin Oncol (2011) 0.79
A gap in disease-specific survival between younger and older adults with de novo metastatic renal cell carcinoma: results of a SEER database analysis. Clin Genitourin Cancer (2013) 0.79
Small cell bladder cancer: biology and management. Semin Oncol (2012) 0.78
FDG PET/CT demonstration of pancreatic metastasis from prostate cancer. Clin Nucl Med (2011) 0.78
Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experience. World J Urol (2008) 0.78
Pain management, supportive and palliative care in patients with renal cell carcinoma. BJU Int (2007) 0.78
Metastatic adrenocortical carcinoma with a prolonged response to mitotane. Oncology (Williston Park) (2014) 0.77
Molecular prognostic factors in bladder cancer. BJU Int (2005) 0.77
Blood cells and their use in active immunotherapy of prostate cancer. Hum Vaccin Immunother (2012) 0.77
Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors. Cancer Chemother Pharmacol (2014) 0.76
The future in advanced prostate cancer: take your partners or is the last dance for me? Rev Urol (2004) 0.75
Perioperative chemotherapy for urothelial cancer: how have we made a "sow's ear" out of a chemotherapy-sensitive tumor? Cancer (2009) 0.75
COOPERATIVE GROUP TRIALS - SOUTHWEST ONCOLOGY GROUP (SWOG) INNOVATIONS IN ADVANCED PROSTATE CANCER. Ther Adv Med Oncol (2009) 0.75
Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2017) 0.75
Subclinical haemostatic activation and current surgeon volume predict bleeding with open radical retropubic prostatectomy. BJU Int (2008) 0.75
The role of surrogate markers in the management of men with metastatic castration-resistant prostate cancer. Clin Adv Hematol Oncol (2011) 0.75
Salvage chemotherapy for refractory germ cell tumors. Oncology (Williston Park) (2014) 0.75